Plus Therapeutics Files Proxy Materials

TL;DR

PLUS proxy materials filed, governance in motion.

AI Summary

Plus Therapeutics, Inc. (formerly Cytori Therapeutics, Inc.) filed a Definitive Additional Materials proxy statement on July 12, 2024. This filing relates to the company's proxy materials, which were previously filed. The company's principal executive offices are located at 4200 Marathon Blvd., Suite 200, Austin, TX 78756.

Why It Matters

This filing indicates that Plus Therapeutics is proceeding with corporate governance matters, likely related to upcoming shareholder votes or meetings, which are crucial for company direction and decision-making.

Risk Assessment

Risk Level: low — This is a routine proxy filing and does not contain new financial information or significant corporate actions that would inherently increase risk.

Key Players & Entities

• PLUS THERAPEUTICS, INC. (company) — Registrant
• CYTORI THERAPEUTICS, INC. (company) — Former company name
• MACROPORE INC (company) — Former company name
• 4200 MARATHON BLVD. SUITE 200 AUSTIN TX 78756 (company) — Business and mailing address

FAQ

Filing Documents

• edge20019156x3_defa14a.htm (DEFA14A) — 12KB
• logo_plustherapeutics.jpg (GRAPHIC) — 1014KB
• 0001140361-24-033065.txt ( ) — 1410KB

From the Filing

14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under 240.14a-12 Plus Therapeutics, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required Fee paid previously with preliminary materials Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 Plus Therapeutics, Inc. Supplement to the Definitive Proxy Statement for the 2024 Annual Meeting of Stockholders to be held on Thursday, August 15, 2024 Supplement No. 1 to Definitive Proxy Statement Dated July 10, 2024 Plus Therapeutics, Inc. (the "Company") is filing this amendment and supplement (this "Supplement") dated July 12, 2024 to its definitive proxy statement dated July 10, 2024 (the "Proxy Statement"), relating to the Company's 2024 Annual Meeting of Stockholders (the "Annual Meeting") to be held on August 15, 2024. We are providing this Supplement solely to clarify the total number of shares of Common Stock available for grant under the Plus Therapeutics, Inc. 2015 New Employee Incentive Plan, which is used for awards that are intended to constitute "employment inducement awards" under applicable Nasdaq listing rules . The total number of shares of Common Stock available for grant as of the close of business on July 5, 2024 under the Plus Therapeutics, Inc. 2015 New Employee Incentive Plan is 62,908, which is the number of available shares disclosed on page 30 of the Proxy Employee Incentive Plan on page 40 of the Proxy Statement under the heading " Information regarding Equity Incentive Program, Dilution and Overhang " is hereby replaced with 62,908 shares of Common Stock . This Supplement should be read in conjunction with the Proxy Proxy Statement for instructions on how to do so. Capitalized terms used but not otherwise defined in this Supplement have the meanings assigned to those terms in the Proxy Statement. This Supplement should be read in conjunction with the Proxy

View Full Filing

View this DEFA14A filing on SEC EDGAR